News & Updates

Back to All News

Lankenau Institute for Medical Research contracts with L2C Partners to manage and commercialize inventions in biomedicine and health care

February 25, 2019 Research News

Lankenau Institute for Medical Research (LIMR), the research division of Main Line Health, will manage and commercialize its growing portfolio of biomedical and health care inventions through an agreement with L2C Partners, a Wynnewood, Pa.-based company that specializes in technology transfer and commercialization services for research centers and educational institutions.

“We’re excited to work with the technology-commercialization experts at L2C Partners to advance clinical development of our portfolio of biomedical inventions,” said George Prendergast, PhD, president and CEO of LIMR. “In the past several years, we have expanded the number of unique technologies invented by our faculty. We look forward to working with L2C to help advance those technologies to the clinic, where they may be able to help patients live longer and healthier lives.”

In addition to conducting biomedical research, LIMR’s resident faculty develop new biopharmaceutical and medical device technologies, particularly in the fields of cancer, cardiovascular disease, autoimmune disorders and regenerative medicine. While assisting LIMR in managing and commercializing its patent portfolio, L2C Partners will also help LIMR manage growth at Main Line Health in healthcare information technology, software applications and population health tools aimed at improving patient care.

L2C Partners helps institutions benefit academically and financially by making more inventions and better-quality intellectual property (IP) available to the life sciences, technology and other industries. The L2C team frequently uncovers unidentified commercialization opportunities and increases its clients’ command of valuable IP.

“The highly regarded LIMR scientists have developed an impressive catalog of IP that is ready for licensing, and we envision many opportunities to help them commercialize those inventions for the betterment of patients,” said Merle Gilmore, founder and CEO of L2C Partners. “Perhaps just as exciting for the L2C team is to support LIMR innovators as they move their creative ideas to invention and then on to society.”

Visit the LIMR website for the full list of LIMR-developed IP and technologies.

About Main Line Health

Founded in 1985, Main Line Health is a not-for-profit health system serving portions of Philadelphia and its western suburbs. Main Line Health’s commitment—to deliver advanced medicine to treat and cure disease while also playing an important role in prevention and disease management as well as training physicians and other health care providers—reflects our intent to keep our community and ourselves well ahead. A team of more than 10,000 employees and 2,000 physicians care for patients throughout the Main Line Health system.

At Main Line Health’s core are four of the region’s most respected acute care hospitals—Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital—as well as one of the nation’s recognized facilities for rehabilitative medicine, Bryn Mawr Rehabilitation Hospital.

The Main Line Health system also includes Mirmont Treatment Center for drug and alcohol recovery; Main Line Health HomeCare & Hospice, which includes skilled home health care, hospice and home infusion services; Main Line Health Centers, primary and specialty care, lab and radiology, and other outpatient services located in Broomall, Collegeville, Concordville, Exton and Newtown Square; Lankenau Institute for Medical Research, a biomedical research organization; and Main Line HealthCare, one of the region’s largest multispecialty physician networks.

Main Line Health is the recipient of numerous awards for quality care and service, including System Magnet® designation, the nation’s highest distinction for nursing excellence, the Mid-Atlantic Alliance for Performance Excellence (MAAPE) Excellence Award, and recognition as among the nation’s best employers by Forbes magazine. Main Line Health is committed to creating an environment of diversity, respect and inclusion and has proudly embraced the American Hospital Association’s #123forEquity Pledge to Act to eliminate disparities in care. We are dedicated to advancing patient-centered care, education and research to help our community stay healthy.

About Lankenau Institute for Medical Research

Lankenau Institute for Medical Research (LIMR) is a nonprofit biomedical research institute located on the campus of Lankenau Medical Center and is part of Main Line Health. Founded in 1927, LIMR’s mission is to improve human health and well-being. Faculty and staff are devoted to advancing innovative new approaches to formidable medical challenges, including cancer, cardiovascular disease, gastrointestinal disorders and autoimmune diseases, such as diabetes and arthritis. LIMR’s principal investigators conduct basic, preclinical and translational research, using their findings to explore ways to improve disease detection, diagnosis, treatment and prevention. They are committed to extending the boundaries of human health through technology transfer and training of the next generation of scientists and physicians.

About L2C Partners

L2C Partners offers institutions and research organizations expert outsourced technology transfer and commercialization services. Committed to innovators and to moving inventions from the lab (or the studio) to society, L2C helps its clients optimize the opportunity posed by an existing gap in the life sciences/technology/manufacturing ecosystem. L2C Partners currently supports health system, research institution, college and university clients across the eastern United States. The company, powered by veteran business and tech transfer executives, is headquartered in Wynnewood, Pa.

Contact

Mary Kate Coghlan
Communications Specialist
Office: 484.580.1028
Cell: 610.308.6675
coghlanm@mlhs.org